Claims
- 1. A compound having the general formula ##STR3## wherein: n is 1 or 2;
- R.sup.1 is hydrogen or C.sub.1 -C.sub.2 alkyl;
- R.sup.2 is hydrogen or C.sub.1 -C.sub.3 alkyl;
- R.sup.3 is C.sub.1 -C.sub.4 alkyl or phenyl C.sub.1 -C.sub.4 alkyl;
- R.sup.4 and R.sup.5 taken together with the adjacent nitrogen to which they are attached complete a heterocyclic ring having 4 to 7 carbon atoms;
- R.sup.6 and R.sup.7 independently are hydrogen, hydroxy, halogen, nitro, C.sub.1 -C.sub.3 alkoxy, or C.sub.1 -C.sub.3 alkyl, provided that at least one of R.sup.6 and R.sup.7 is hydrogen, and
- X is a therapeutically acceptable anion.
- 2. The compound of claim 1 wherein R.sup.3 is C.sub.1 -C.sub.4 alkyl and R.sup.6 and R.sup.7 independently are hydrogen, halogen, nitro, C.sub.1 -C.sub.3 alkoxy, or C.sub.1 -C.sub.3 alkyl.
- 3. The compound of claim 2 wherein n is 1.
- 4. The compound of claim 1 wherein R.sup.6 is halogen or nitro.
- 5. The compound of claim 1 wherein n is 2 and R.sup.6 is halogen or nitro.
- 6. The compound of claim 1 wherein R.sup.1 is C.sub.1 -C.sub.2 alkyl and R.sup.2 is hydrogen.
- 7. The compound according to claim 1 which is N-methyl-N-(4-phenylbutyl)hexahydroazepinium bromide.
- 8. The compound according to claim 1 which is N-methyl-N-(4-phenylbutyl)-tetrahydropyrrolium bromide.
- 9. The compound according to claim 1 which is N-methyl-N-(4-phenylbutyl)piperidinium methanesulfonate.
- 10. A method of treating re-entrant arrhythmias in humans suffering from such arrhythmias and in need of treatment or in humans suspected of developing a re-entrant arrhythmia comprising administering to such subject an antiarrhythmically effective dose of a compound of claim 1.
- 11. The method according to claim 10 employing a compound wherein R.sup.3 is C.sub.1 -C.sub.4 alkyl and R.sup.6 and R.sup.7 independently are hydrogen, halogen, nitro, C.sub.1 -C.sub.3 alkoxy, or C.sub.1 -C.sub.3 alkyl.
- 12. A pharmaceutical formulation for the treatment of re-entrant arrhythmias in humans comprising as active ingredient an antiarrhythmic amount of a quaternary ammonium salt of claim 1 in combination with one or more pharmaceutically acceptable diluents or carriers therefor.
- 13. The formulation of claim 12 employing a compound wherein R.sup.3 is C.sub.1 -C.sub.4 alkyl, and R.sup.6 and R.sup.7 independently are hydrogen, halogen, nitro, C.sub.1 -C.sub.3 alkoxy or C.sub.1 -C.sub.3 alkyl.
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a division of Ser. No. 102,043 filed Dec. 10, 1979, now U.S. Pat. No. 4,289,787, which was a continuation-in-part of Ser. No. 861,789, filed Dec. 19, 1977 now abandoned.
US Referenced Citations (7)
Foreign Referenced Citations (1)
Number |
Date |
Country |
1157541 |
Jul 1969 |
GBX |
Non-Patent Literature Citations (4)
Entry |
Chem. Abst. 92, 110,643u (1980)-Molloy et al. |
Pharmac. 37, 555-584 (1969)-Barlow et al. |
European J. of Pharm. 35,245-252 (1976)-Lien et al. |
Chem. Abst. 54, 19588(f) (1960)-Morikawa. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
102043 |
Dec 1979 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
861789 |
Dec 1977 |
|